Invitae is a growth leader in genetic testing. The company is growing at full speed, and it has enormous room for expansion going forward. Lack of profitability and share dilution are the main ...

Invitae's shares have plummeted as the company slashed its growth forecast to avoid bankruptcy. Revenue for Q2 was slightly above estimates but down 12% YoY, and analyst revenue estimates have ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

Shares of San Francisco-based genetic testing and data company Invitae Corporation (NVTA) exploded higher after reporting earnings Tuesday night. After 6.5 trading hours on Wednesday, Invitae stock ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Its been a big, albeit wholly erratic, year for Invitae (NYSE: NVTA), one of the tech stock winners of 2020. On March 19, 2020, the stock sat at $7.43. In mid-December, it topped $61. Now, after a ...